



ASX ANNOUNCEMENT

7 December 2023

Receipt of Clinichain Trial Funds

CardieX Limited (ASX: CDX) (**CardieX**, the **Company**) is pleased to advise the Company has today received US\$4.12 million (~A\$6.26 million¹), being the full settlement of all contractual payments in relation to the Clinichain clinical trial.

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Rod Hinchcliffe
rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton
melissa.hamilton@mcpartners.com.au

Investor Relations – USA

Matt Selinger
Managing Director, Integrous Communications
mselinger@integcom.com

About CardieX

CardieX is a medical technology company that develops and markets non-invasive patient monitoring technologies for assessing vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor® vascular biomarker technology. CardieX is listed on the Australian Stock Exchange ("CDX").

¹ Based on the exchange rate of 1 AUD: 0.6581 USD on Reserve Bank of Australia at 6 December 2023.